PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDecitabine
Dacogen(decitabine)
Dacogen, Decitabine, Inaqovi, Inqovi (decitabine) is a small molecule pharmaceutical. Decitabine was first approved as Dacogen on 2006-05-02. It is used to treat myelodysplastic syndromes in the USA. It has been approved in Europe to treat myeloid leukemia. It is known to target cytidine deaminase.
Download report
Favorite
FDA Novel Drug Approvals 2020
SARS-CoV-2 Interaction
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
Trade Name
FDA
EMA
Decitabine (discontinued: Dacogen, Decitabine)
Combinations
Inqovi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Decitabine
Tradename
Company
Number
Date
Products
DACOGENOtsukaN-021790 DISCN2006-05-02
1 products, RLD
DECITABINESun Pharmaceutical IndustriesN-205582 DISCN2014-01-28
1 products, RLD
Hide discontinued
Cedazuridine
+
Decitabine
Tradename
Company
Number
Date
Products
INQOVITaiho OncologyN-212576 RX2020-07-07
1 products, RLD, RS
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myelodysplastic syndromes—D009190D46
Agency Specific
FDA
EMA
Expiration
Code
CEDAZURIDINE / DECITABINE, INQOVI, OTSUKA
2027-07-07ODE-316
2025-07-07NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Cedazuridine / Decitabine, Inqovi, Otsuka
82688002030-08-22DPU-2864, U-2865, U-2866, U-2867
86180752028-10-16U-2864, U-2867
95673632028-10-16DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BC: Pyrimidine analogues, antineoplastic antimetabolites
— L01BC08: Decitabine
HCPCS
Code
Description
J0893
Injection, decitabine (sun pharma) not therapeutically equivalent to j0894, 1 mg
J0894
Injection, decitabine, 1 mg
Clinical
Clinical Trials
619 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470—C92.012113537214261
LeukemiaD007938—C958311434211205
Myeloid leukemiaD007951—C92709431210174
Myelodysplastic syndromesD009190—D467310517312174
PreleukemiaD011289——42621239108
SyndromeD013577——334693986
LymphomaD008223—C85.9192842142
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.010911120
Large b-cell lymphoma diffuseD016403—C83.371141—20
Hematopoietic stem cell transplantationD018380——213101—16
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8037194—245
RecurrenceD012008——25175—240
Myelomonocytic leukemia chronicD015477—C93.116214—138
Myelomonocytic leukemia juvenileD054429—C93.39114—225
Myeloproliferative disordersD009196—D47.113141—124
Myelodysplastic-myeloproliferative diseasesD054437——671——12
Myelomonocytic leukemia acuteD015479—C92.5282——12
Refractory anemia with excess of blastsD000754—D46.2353—110
T-cell lymphomaD016399——333——9
Ovarian neoplasmsD010051EFO_0003893C56581——9
Show 40 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—89———15
Primary myelofibrosisD055728—D47.456——111
Hematologic neoplasmsD019337——84——111
Lymphoid leukemiaD007945—C9165——110
Breast neoplasmsD001943EFO_0003869C5075———10
Non-small-cell lung carcinomaD002289——86———10
Lung neoplasmsD008175—C34.9084———10
CarcinomaD002277—C80.067———9
Blast crisisD001752——45———8
Colorectal neoplasmsD015179——65——18
Show 80 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell chronic lymphocytic leukemiaD015451—C91.14————4
NeuroblastomaD009447EFO_0000621—3————3
Head and neck neoplasmsD006258——3————3
Squamous cell carcinoma of head and neckD000077195——3————3
ThrombocytosisD013922—D75.832————2
Promyelocytic leukemia acuteD015473—C92.42————2
Mantle-cell lymphomaD020522—C83.12————2
Burkitt lymphomaD002051—C83.72————2
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.22————2
Small cell lung carcinomaD055752——2————2
Show 23 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—————22
Chronic painD059350——————22
FibromyalgiaD005356EFO_0005687M79.1————22
FrailtyD000073496—R53.1————11
Liver transplantationD016031EFO_0010682—————11
Colonic neoplasmsD003110—C18————11
Pulmonary hypertensionD006976EFO_0001361I27.20————11
OsteoporosisD010024EFO_0003882M81.0————11
Iron overloadD019190——————11
Hiv infectionsD015658EFO_0000764B20————11
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDecitabine
INNdecitabine
Description
5-aza-2'-deoxycytidine is a 2'-deoxyribonucleoside.
Classification
Small molecule
Drug classnucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Identifiers
PDB—
CAS-ID2353-33-5
RxCUI—
ChEMBL IDCHEMBL1201129
ChEBI ID50131
PubChem CID451668
DrugBankDB01262
UNII ID776B62CQ27 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CDA
CDA
Organism
Homo sapiens
Gene name
CDA
Gene synonyms
CDD
NCBI Gene ID
Protein name
cytidine deaminase
Protein synonyms
Cytidine aminohydrolase, cytosine nucleoside deaminase, small cytidine deaminase
Uniprot ID
Mouse ortholog
Cda (72269)
cytidine deaminase (Q9D7V3)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: 2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w..., Center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al..., Dacarbazine, Standardized bermuda grass pollen standardized kentucky bluegrass pollen standardized meadow fescue grass pollen standardized orchard grass pollen ..., Standardized bermuda grass standardized kentucky blue (june) grass standardized meadow fescue grass standardized orchard grass standardized perenni...
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
111,238 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use